164 related articles for article (PubMed ID: 33498270)
1. The Periphery of Salivary Gland Carcinoma Tumors Reveals a PD-L1/PD-1 Biomarker Niche for the Evaluation of Disease Severity and Tumor-Immune System Interplay.
Kuchar M; Strizova Z; Capkova L; Komarc M; Skrivan J; Bartunkova J; Smrz D; Plzak J
Biomedicines; 2021 Jan; 9(2):. PubMed ID: 33498270
[TBL] [Abstract][Full Text] [Related]
2. Fas-Fas Ligand Interplay in the Periphery of Salivary Gland Carcinomas as a New Checkpoint Predictor for Disease Severity and Immunotherapy Response.
Strizova Z; Kuchar M; Capkova L; Komarc M; Skrivan J; Bartunkova J; Plzak J; Smrz D
Biomedicines; 2021 Apr; 9(4):. PubMed ID: 33917866
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of programed death ligand-1 and ligand-2 co-expression in salivary gland carcinomas.
Nakano T; Takizawa K; Uezato A; Taguchi K; Toh S; Masuda M
Oral Oncol; 2019 Mar; 90():30-37. PubMed ID: 30846173
[TBL] [Abstract][Full Text] [Related]
4. The expression profiles of CD47 in the tumor microenvironment of salivary gland cancers: a next step in histology-driven immunotherapy.
Votava M; Bartolini R; Capkova L; Smetanova J; Jiri V; Kuchar M; Kalfert D; Plzak J; Bartunkova J; Strizova Z
BMC Cancer; 2022 Sep; 22(1):1021. PubMed ID: 36171566
[TBL] [Abstract][Full Text] [Related]
5. Programmed death ligand-1 expression is associated with poor disease free survival in salivary gland carcinomas.
Mukaigawa T; Hayashi R; Hashimoto K; Ugumori T; Hato N; Fujii S
J Surg Oncol; 2016 Jul; 114(1):36-43. PubMed ID: 27111278
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of PD-L1 expression in tumor infiltrating immune cells in cancers: A meta-analysis.
Zhao T; Li C; Wu Y; Li B; Zhang B
PLoS One; 2017; 12(4):e0176822. PubMed ID: 28453554
[TBL] [Abstract][Full Text] [Related]
7. The expression of PD-L1 in salivary gland carcinomas.
Vital D; Ikenberg K; Moch H; Rössle M; Huber GF
Sci Rep; 2019 Sep; 9(1):12724. PubMed ID: 31484986
[TBL] [Abstract][Full Text] [Related]
8. The expression of programed death ligand-1 could be related with unfavorable prognosis in salivary duct carcinoma.
Sato F; Akiba J; Kawahara A; Naito Y; Ono T; Takase Y; Murata K; Abe H; Yamaguchi T; Miyoshi H; Abe Y; Mihara Y; Tanikawa M; Akashi M; Kurose H; Umeno H; Yano H
J Oral Pathol Med; 2018 Aug; 47(7):683-690. PubMed ID: 29719073
[TBL] [Abstract][Full Text] [Related]
9. Incidence and Prognostic Significance of PD-L1 Expression in High-Grade Salivary Gland Carcinoma.
Fang Q; Wu Y; Du W; Zhang X; Chen D
Front Oncol; 2021; 11():701181. PubMed ID: 34513680
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Impact of PD-L1 Expression in Malignant Salivary Gland Tumors as Assessed by Established Scoring Criteria: Tumor Proportion Score (TPS), Combined Positivity Score (CPS), and Immune Cell (IC) Infiltrate.
Witte HM; Gebauer N; Lappöhn D; Umathum VG; Riecke A; Arndt A; Steinestel K
Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32260165
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients.
Kawazoe A; Kuwata T; Kuboki Y; Shitara K; Nagatsuma AK; Aizawa M; Yoshino T; Doi T; Ohtsu A; Ochiai A
Gastric Cancer; 2017 May; 20(3):407-415. PubMed ID: 27629881
[TBL] [Abstract][Full Text] [Related]
12. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L; Liu Y; Wang Y
Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
[TBL] [Abstract][Full Text] [Related]
13. Foci of Programmed Cell Death-Ligand 1 (PD-L1)-positive Tumor Areas With Tumor-infiltrating Leukocytes (TILs) Evocative of a PD-1/PD-L1-related Adaptive Immune Resistance are Frequent in Merkel Cell Carcinoma.
Bénigni P; Guénolé M; Bonsang B; Marcorelles P; Schick U; Uguen A
Appl Immunohistochem Mol Morphol; 2020 Jan; 28(1):17-22. PubMed ID: 31343994
[TBL] [Abstract][Full Text] [Related]
14. PD-L1 expression in malignant salivary gland tumors.
Harada K; Ferdous T; Ueyama Y
BMC Cancer; 2018 Feb; 18(1):156. PubMed ID: 29409471
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of PD-1 and PD-L1 positive tumor-infiltrating immune cells in ovarian carcinoma.
Buderath P; Mairinger F; Mairinger E; Böhm K; Mach P; Schmid KW; Kimmig R; Kasimir-Bauer S; Bankfalvi A; Westerwick D; Hager T
Int J Gynecol Cancer; 2019 Nov; 29(9):1389-1395. PubMed ID: 31492714
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of PD-L1 and PD-1 expression in aggressive eyelid sebaceous gland carcinoma and its clinical significance.
Jayaraj P; Sen S
Indian J Ophthalmol; 2019 Dec; 67(12):1983-1987. PubMed ID: 31755433
[TBL] [Abstract][Full Text] [Related]
17. The expression of the adenosine pathway markers CD39 and CD73 in salivary gland carcinomas harbors the potential for novel immune checkpoint inhibition.
Bauer A; Gebauer N; Knief J; Tharun L; Arnold N; Riecke A; Steinestel K; Witte HM
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3193-3208. PubMed ID: 35902382
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Role of Programmed Death Ligand-1 on Tumor-Infiltrating Immune Cells in "High-Risk" Patients Following Radical Cystectomy: A Retrospective Cohort Study.
Lee CU; Lee DH; Song W
Front Oncol; 2021; 11():706503. PubMed ID: 34490106
[TBL] [Abstract][Full Text] [Related]
19. Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer.
Drakes ML; Mehrotra S; Aldulescu M; Potkul RK; Liu Y; Grisoli A; Joyce C; O'Brien TE; Stack MS; Stiff PJ
J Ovarian Res; 2018 May; 11(1):43. PubMed ID: 29843813
[TBL] [Abstract][Full Text] [Related]
20. Immune Checkpoint Ligand Reverse Signaling: Looking Back to Go Forward in Cancer Therapy.
Lecis D; Sangaletti S; Colombo MP; Chiodoni C
Cancers (Basel); 2019 May; 11(5):. PubMed ID: 31060225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
